# Phase 3 thromboembolism trials recruiting: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 3 for thromboembolism that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 thromboembolism trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/thromboembolism

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 15, 2026 | NCT07821008 | TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study | University Hospital, Toulouse | Phase 3 | Not yet recruiting | Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821008) |
| July 13, 2026 | NCT07697599 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted... | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 1,908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697599) |
| March 25, 2026 | NCT07493304 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493304) |
| February 25, 2026 | NCT07432529 | Design and Rationale of the COLT Study | Azienda Sanitaria Locale ASL 6, Livorno | Phase 3 | Not yet recruiting | Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE), Venous Insufficiency | 940 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432529) |
| February 24, 2026 | NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 2,628 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430956) |
| February 13, 2026 | NCT07410117 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Cancer-Associated Thrombosis (CAT) | 1,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410117) |
| November 14, 2025 | NCT07228663 | Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | McMaster University | Phase 3 | Not yet recruiting | Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228663) |
| August 24, 2025 | NCT07140211 | Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Venous Thromboembolism (VTE), Postpartum | 9,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140211) |
| June 11, 2025 | NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015905) |
| June 4, 2025 | NCT07005024 | DOAC - Dosing Options in AntiCoagulation Prophylaxis | University of Vermont | Phase 3 | Recruiting | Cancer, VTE (Venous Thromboembolism) | 996 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07005024) |
| March 6, 2025 | NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | Quercis Pharma AG | Phase 3 | Recruiting | Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861088) |
| October 8, 2024 | NCT06628778 | Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for... | Johns Hopkins All Children's Hospital | Phase 3 | Not yet recruiting | Venous Thromboembolism (VTE) | 802 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06628778) |
| August 30, 2024 | NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | Not yet recruiting | Multiple Myeloma, Venous Thromboembolism | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580223) |
| July 10, 2024 | NCT06494878 | The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity | University of Calgary | Phase 3 | Recruiting | Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin | 8,805 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494878) |
| June 4, 2024 | NCT06440694 | Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Venous Thromboembolism | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06440694) |
| May 1, 2024 | NCT06393868 | Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Venous Thromboembolism, Gastro Intestinal Bleeding, Blood Clot | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393868) |
| January 8, 2024 | NCT06195540 | RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing | University Hospital, Angers | Phase 3 | Recruiting | Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism, Lower Limb Trauma, Thromboprophylaxis, Immobilisation | 1,424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06195540) |
| November 25, 2022 | NCT05627375 | Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets | Centre Hospitalier Universitaire de Saint Etienne | Phase 3 | Recruiting | Venous Thromboembolic Disease | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05627375) |
| January 20, 2022 | NCT05198960 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive... | University Hospital, Brest | Phase 3 | Recruiting | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 1,308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198960) |
| August 31, 2021 | NCT05029063 | Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Venous Thromboembolism, Cancer | 1,828 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05029063) |
| March 24, 2020 | NCT04319627 | Statins for Venous Event Reduction in Patients With Venous Thromboembolism | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome | 2,700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04319627) |
| February 6, 2020 | NCT04257487 | Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) | Arianna Anticoagulazione Foundation | Phase 3 | Recruiting | Venous Thromboembolism, Anticoagulant, Elderly | 1,455 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04257487) |
| August 17, 2018 | NCT03636295 | Low INR to Minimize Bleeding With Mechanical Valves Trial | Population Health Research Institute | Phase 3 | Recruiting | Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement | 2,625 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03636295) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 5 |
| Ottawa Hospital Research Institute | 4 |
| Arianna Anticoagulazione Foundation | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Johns Hopkins All Children's Hospital | 1 |
| University of Vermont | 1 |
| McMaster University | 1 |
| University of Calgary | 1 |
| University Hospital, Angers | 1 |
| Quercis Pharma AG | 1 |
| Azienda Sanitaria Locale ASL 6, Livorno | 1 |
| Population Health Research Institute | 1 |
| University Hospital, Toulouse | 1 |
| University Hospital, Brest | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |

## By country

| Country | Trials |
| --- | --- |
| Canada | 8 |
| United States | 7 |
| France | 6 |
| Italy | 4 |
| Japan | 3 |
| China | 2 |
| Bulgaria | 2 |
| Romania | 2 |
| South Korea | 2 |
| Belgium | 2 |
| Denmark | 2 |
| Ireland | 2 |
| Netherlands | 2 |
| Poland | 2 |
| United Kingdom | 2 |
| Georgia | 2 |
| Botswana | 1 |
| Brazil | 1 |
| Cameroon | 1 |
| Germany | 1 |
| Kenya | 1 |
| Nepal | 1 |
| Pakistan | 1 |
| Russia | 1 |
| Saudi Arabia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
